Introduction
============

Hepatocellular carcinoma (HCC) is a common type of cancer that is usually diagnosed at an advanced stage. Transarterial chemoembolization (TACE) is widely used to treat HCC patients who cannot be given curative treatments ([@b1-etm-0-0-5540],[@b2-etm-0-0-5540]). The TACE protocol includes intra-arterial chemotherapy with lipiodol and chemotherapeutic agents, followed by selective vascular embolization with gelfoam. A study comparing TACE with best supportive care found a distinct survival benefit with TACE ([@b1-etm-0-0-5540],[@b2-etm-0-0-5540]). In addition, the transarterial chemolipidolization (TACL) protocol includes transarterial infusion of chemotherapeutic agents in a mixture of lipiodol without gelfoam embolization ([@b3-etm-0-0-5540]--[@b5-etm-0-0-5540]). TACL may be performed multiple times with minimization of vascular injury and also provided the benefit of downsizing of HCC ([@b3-etm-0-0-5540]--[@b5-etm-0-0-5540]). However, TACE causes a range of minor and major complications, including acute cholecystitis, ischaemic hepatitis, pulmonary thromboembolism, liver abscess, ischaemic biliary strictures and, less frequently, pancreatic damage. In particular, TACE may cause injury to the hepatic artery, leading to arterial spasms and inflammatory constriction, and occlusion or dissection in severe cases ([@b6-etm-0-0-5540]--[@b8-etm-0-0-5540]). Drug-eluting beads (DC beads) loaded with chemotherapeutic agents have been developed, which facilitate slow drug release upon injection. This may increase the intensity and duration of tumour ischaemia as a result of enhancing drug delivery to the tumour ([@b9-etm-0-0-5540],[@b10-etm-0-0-5540]). Several studies have demonstrated that TACE with DC beads has fewer systemic side effects and less toxicity than conventional TACE ([@b10-etm-0-0-5540]--[@b12-etm-0-0-5540]). However, the present case reports on the case of a patient who unexpectedly experienced sustained multiple-organ ischaemia including pancreatitis, peptic ulcer and multiple liver-spleen infarctions after TACE with DC beads. This case is unusual but suggests the requirement for careful use of TACE with DC beads and early recognition of ischaemic complications.

Case report
===========

A 66-year-old man with HCC was admitted to the Department of Internal Medicine, Incheon St. Mary\'s Hospital, (Incheon, South Korea) due to diffuse abdominal pain that began 1 month after TACE with DC beads. Six years previously, at the same hospital the patient had been diagnosed with a single 2.6-cm HCC lesion in segment 7 (Barcelona Clinic Liver Cancer Class A, Okuda Stage 1, Eastern Cooperative Oncology Group Status 1). The patient refused surgical resection and was treated with TACL using adriamycin (50 mg). Of note, the protocol at our institution does not use conventional TACE but TACL. The patient had been treated with 19 cycles of on-demand TACL over 6 years, whenever a new nodule developed. No distant metastasis was observed over this time period. The initial HCC necrotized following 4 cycles of TACL. Subsequently, a 2-cm HCC in segment 4 developed and was treated with 10 cycles of TACL. After 18 months of complete remission, a 2.2-cm HCC in segment 3 developed and necrotized for 3 cycles of TACL. After 10 months, a 2.4-cm HCC in segment 6 newly developed and was treated two times with TACL. However, a viable remnant of the last target lesion was still present ([Fig. 1](#f1-etm-0-0-5540){ref-type="fig"}). Finally, the patient was treated by TACE with DC beads to reduce the frequency of TACL at 1 month prior to the current admission ([Fig. 1A](#f1-etm-0-0-5540){ref-type="fig"}). The patient had possessed an intact hepatic artery at the first TACL procedure, but narrowing and damage of the artery progressed with multiple TACLs ([Fig. 2](#f2-etm-0-0-5540){ref-type="fig"}). The current angiogram revealed that both hepatic arteries were narrow, and thin aberrant collateral vessels to the tumour were observed ([Fig. 2B](#f2-etm-0-0-5540){ref-type="fig"}). To prepare DC beads, 50 mg doxorubicin was loaded in a 2-ml vial containing 100--300 µm beads (Biocompatibles, Farnham, UK) with nonionic contrast media (Imeron 300; Bracco-Altana, Konstanz, Germany). After saturation of the DC beads, the radiologist started to infuse them at a rate of 1 ml/min. However, he unexpectedly encountered difficulties infusing the DC beads into the right hepatic artery, and detected a small backward flow of the DC beads. The infusion of beads was immediately stopped and no additional stained tumour was seen on hepatic angiography.

On the current admission, the patient complained of continuous abdominal discomfort, particularly in the periumbilical area. Liver dynamic computed tomography (CT) confirmed severe bile duct injury, liver infarction in the right hepatic lobe and newly developed necrotizing pancreatitis ([Fig. 1B](#f1-etm-0-0-5540){ref-type="fig"}). The targeted HCC nodule exhibited an increased area of necrosis compared with that seen 1 month earlier ([Fig. 1B](#f1-etm-0-0-5540){ref-type="fig"}). Gastrofibroscopy (GFS) revealed multiple active ulcers on the antrum and body of the stomach and oedematous, ulcerative lesions on the proximal second portion of the duodenum ([Fig. 3](#f3-etm-0-0-5540){ref-type="fig"}). On the pathology specimen of the duodenum, DC-beads that had passed through small vessels in the duodenal connective tissue were observed ([Fig. 4](#f4-etm-0-0-5540){ref-type="fig"}).

After admission, the patient\'s symptoms were treated conservatively with broad-spectrum antibiotics, hydration, pain control, anti-ulcer medication and a proteinase inhibitor for necrotizing pancreatitis. His condition had improved 2 weeks after admission. However, at this time-point (44 days after the TACE with DC beads), he developed an elevated temperature of 38.7°C and marked elevations of aspartate aminotransferase, alanine aminotransferase, C-reactive protein and total bilirubin ([Table I](#tI-etm-0-0-5540){ref-type="table"}). Follow-up abdominal CT images revealed a newly developed multifocal liver infarction in the right hepatic lobe and a newly developed partial infarction in the spleen ([Fig. 1C](#f1-etm-0-0-5540){ref-type="fig"}). Finally, 30 days after admission (2 months after the TACE with DC beads), his symptoms and laboratory results improved ([Table I](#tI-etm-0-0-5540){ref-type="table"}). On the subsequent GFS examination, the gastric ulcer and duodenal ulcer exhibited signs of healing ([Fig. 3B](#f3-etm-0-0-5540){ref-type="fig"}) and the patient was discharged.

After recovering from the multiple hepatic infarcts and ongoing ischaemic changes, the patient had no additional DC bead-associated multi-organ complications until he died due to the progression of HCC at 11 months after TACE with DC beads.

Discussion
==========

The present case report showed a severe case of ischaemic inflammation of multiple organs after TACE with DC beads. A European multicentre randomized study reported that TACE with DC beads is more effective than conventional TACE in terms of disease control and tolerability ([@b13-etm-0-0-5540]). The use of DC beads allowing the slow release of chemotherapy over time has been correlated with fewer systemic complications, including nausea, vomiting, asthenia and alopecia compared with conventional TACE ([@b11-etm-0-0-5540],[@b13-etm-0-0-5540]). In the case of TACE with DC beads, severe adverse events including hepatic insufficiency, infarction or hepatic abscess, and tumour rupture may occur, but are associated with an excellent tumour response. Such complications are rare, with a reported incidence of 3--4% and 30-day mortality rates of 1--4% ([@b14-etm-0-0-5540],[@b15-etm-0-0-5540]), and usually occur within 30 days of the procedure ([@b16-etm-0-0-5540]). A previous study reported that TACE with DC beads was effective for refractory HCC compared with conventional TACE ([@b17-etm-0-0-5540]). A complete response was observed in 40% of the tumours and a partial response was observed in 60% of the tumours. TACE with DC beads elicited a better response than conventional TACE, particularly when the tumours were small and exhibited a delayed enhancement pattern upon angiography. In the present case report, the patient\'s HCC nodule was small.

Several studies have reported hepatic loco-regional toxicities of TACE with DC beads ([@b18-etm-0-0-5540]--[@b22-etm-0-0-5540]). The incidence of biliary injury and intrahepatic biloma were significantly higher following TACE with DC beads ([@b18-etm-0-0-5540]). In the present case report, the patient developed not only bile duct injury and liver infarction, but also spleen infarction and ischaemic duodenal ulcers over several months. Known risk factors associated with ischaemic organ damage after conventional TACE are non-selective embolization, the number of procedures and the volume of embolic material ([@b22-etm-0-0-5540],[@b23-etm-0-0-5540]). In particular, the baseline prothrombine value and the dose of chemotherapy have been correlated with the occurrence of hepatic loco-regional complications after TACE with DC beads ([@b18-etm-0-0-5540]). In the present case report, the vascular stricture resulting from numerous previous TACE treatments may have contributed to the multi-organ ischemia by causing a reflux of DC beads into the gastroduodenal, right gastric, right gastroepiploic, left gastric or splenic branches of the celiac trunk due to the stenosis of the hepatic artery. The beads displayed in the pathology sample of duodenal tissue suggested such a regurgitation of the DC beads. An animal study in Yucatan pigs demonstrated an increased retention and sustained release of doxorubicin after embolization with loaded DC beads for 28 until up to 90 days after liver embolization ([@b24-etm-0-0-5540]). Thus, ischaemic damage associated with the reflux of DC-beads may continue for \>3 months and is more severe than that produced by conventional TACE ([@b24-etm-0-0-5540],[@b25-etm-0-0-5540]). To prevent this complication, it is important to reduce the backflow of embolic material by placing the catheter tip as close as possible to the distal branches of the hepatic artery as possible, and then carefully injecting the embolic material to avoid regurgitation. Particularly in patients with vessel stricture following previous repeated conventional TACE, the selection of TACE with DC beads as a treatment option should be made with caution.

In conclusion, TACE with DC beads should only be considered with caution, particularly in patients with stenosis of the hepatic artery, and a super-selective procedure is essential to avoid the embolization of DC beads in unintended organs. In addition, even considering its expected favourable antitumour effect, clinicians should be aware of the potential risk of an unusual fatal course after TACE with DC beads.

![(A) Liver dynamic CT performed 2 days before the TACE with DC beads showing a viable remnant tumour (segment 6, arrow). (B) Liver dynamic CT performed on admission due to abdominal pain revealed multi-locular fluid accumulation with enhanced walls in the peripancreatic space and marked irregular right intrahepatic duct dilatation. However, imaging indicated increased necrosis (3 cm) in the lipiodol-laden hepatocellular carcinoma at segment 6. (C) Liver dynamic CT re-performed for fever and abdominal pain after initial improvement (44 days after the TACE with DC beads) revealing newly developed multifocal perfusion defects, suggesting liver and splenic infarction. The peri-pancreatic fluid collection was decreased. DC beads, drug-eluting beads; CT, computed tomography.](etm-15-02-1479-g00){#f1-etm-0-0-5540}

![Angiograms revealing (A) the intact hepatic artery at the first transarterial chemolipidolization procedures and (B) marked narrowing of the right hepatic artery at the time of trans-arterial chemo-embolization with DC beads. The narrowing made infusion of DC beads into the right hepatic artery difficult and produced a backward flow that required immediate cessation of the infusion. DC beads, drug-eluting beads.](etm-15-02-1479-g01){#f2-etm-0-0-5540}

![(A) Gastrofibroscopy revealing an oedematous, ulcerative lesion on the proximal second portion of the duodenum and multiple active ulcers on the angle and body of the stomach at 30 days after TACE with DC beads. (B) Duodenal and gastric ulcers had healed well at 63 days after TACE with DC-beads. DC beads, drug-eluting beads; TACE, trans-arterial chemo-embolization.](etm-15-02-1479-g02){#f3-etm-0-0-5540}

![Haematoxylin-stained DC beads embedded in duodenal connective tissue and surrounded by lymphocytes 30 days after TACE with DC beads (magnification, ×200). DC beads, drug-eluting beads. TACE, transarterial chemoembolization.](etm-15-02-1479-g03){#f4-etm-0-0-5540}

###### 

Laboratory results at various time-points after TACE with DC beads.

  Parameter                     Prior to TACE with beads   Day 30 (Admission)   Day 44 (Fever)   Day 64 (Discharge)
  ----------------------------- -------------------------- -------------------- ---------------- --------------------
  Complete blood cell count                                                                      
    Hemoglobin (g/dl)           12.3                       11.0                 8.9              10.3
    WBC count (10^3^/µl)        10,970                     12,010               9,490            5,830
    Platelet count (10^3^/µl)   197                        345                  59               274
  Blood chemistry                                                                                
    BUN (mg/dl)                 19.1                       30.9                 9.8              15.1
    Creatinine (mg/dl)          0.8                        0.9                  0.7              0.6
    Total protein (g/dl)        6.9                        6.4                  4.7              6.5
    Albumin (g/dl)              3.8                        3.1                  2.4              2.9
    AST (U/l)                   32                         82                   1305             38
    ALT (U/l)                   28                         42                   496              18
    Total bilirubin (mg/dl)     0.5                        1.2                  3.5              2.0
    Direct bilirubin (mg/dl)    0.1                        0.5                  2.3              0.9
    r-GTP (U/l)                 69                         153                  439              459
    ALP (U/l)                   133                        280                  603              475
    Amylase (IU/l)              56                         219                  80               64
    CRP (mg/l)                  4.43                       133.92               133.97           24.66
  Coagulation test                                                                               
    Prothrombin time (INR/%)    1.02                       1.06                 1.31             1.20
  Tumor markers                                                                                  
    AFP (ng/ml)                 190.76                     22.43                                 
    PIVKA II                    367                        70                                    

BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; DC beads, drug-eluting beads; TACE, trans-arterial chemo-embolization; AFP, α-fetoprotein; PIVKA II, acarboxy prothrombin.
